Drug intelligence / Profile preview

RHYK2008

Development stage: Unknown
Lead developer: Shijiazhuang Keren Medical Technology
Modality: Small Molecules
Administration: Oral

Overview

RHYK2008 is a drug candidate being developed by Shijiazhuang Keren Pharmaceutical Technology Co., Ltd. for the treatment of hypertension. While specific details regarding its chemical structure and precise molecular target are not widely disclosed in public clinical databases, it is positioned within the cardiovascular therapeutic area. The drug has undergone clinical evaluation in China to assess its safety, tolerability, and pharmacokinetic profile in healthy volunteers and patients with hypertension.

Beyond the preview

Go deeper on RHYK2008.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RHYK2008.

Explore the full profile